#United States #Orlando #Apnimed #AD109 #ATS 2026

Apnimed Showcases Innovations in Sleep Apnea Treatment at ATS 2026

June 11, 2026 - Apnimed, Inc., a clinical pharmaceutical company committed to developing groundbreaking oral therapies for sleep-related breathing disorders, has recently announced its participation in the American Thoracic Society (ATS) 2026 International Conference. This prestigious event will take place from May 15 to 20 in Orlando, Florida, where Apnimed will present significant findings arising from their pivotal clinical trials.

Multiple Presentations Scheduled

Apnimed's involvement at the conference includes three oral presentations and a late-breaking poster session. These presentations highlight the results of their Phase 3 trials—SynAIRgy and LunAIRo—focused on AD109, Apnimed’s main therapeutic candidate for obstructive sleep apnea (OSA). This marks one of the largest clinical development initiatives of its kind targeting pharmacotherapy for OSA.

Oral Presentation Highlights

1. Title: Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea: A Pooled Analysis of the SynAIRgy and LunAIRo Phase 3 Trials
Time: May 17, 2026 at 2:15 PM - 4:15 PM EDT
Venue: Chapin Theater, OCCC West Concourse
- This session aims to illuminate the pooled analysis from Apnimed's trials, showcasing how AD109 may disrupt the conventional approaches to OSA treatment.

2. Title: AD109 Significantly Reduces Snoring in Patients with Obstructive Sleep Apnea
Time: May 19, 2026 at 9:51 AM - 10:03 AM EDT
Venue: W110A, OCCC West Concourse
- This presentation will discuss the significant reduction in snoring, an essential secondary benefit of AD109 treatment, affecting the quality of life for many OSA patients.

3. Title: Estimated Reduction in Cardiovascular Risk Associated With Hypoxic Burden Improvement With AD109 in the LunAIRo and SynAIRgy Phase 3 Studies for Obstructive Sleep Apnea
Time: May 19, 2026 at 10:15 AM - 10:27 AM EDT
Venue: W110A, OCCC West Concourse
- Emphasizing the cardiovascular risk factor, this analysis reveals how improving oxygenation during sleep can significantly impact long-term health outcomes for OSA patients.

Late-Breaking Poster Presentation

Additionally, a late-breaking feature poster titled Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea: A Pooled Analysis of the SynAIRgy and LunAIRo Phase 3 Trials will be displayed on May 17, 2026, presenting further data on the pharmacological advantages of AD109. This will take place during the thematic poster session dedicated to the mechanisms and physiological control of sleep apnea.

Understanding AD109's Role in OSA Treatment

AD109 combines aroxybutynin, a novel antimuscarinic agent, with atomoxetine, a selective norepinephrine reuptake inhibitor. This oral treatment aims not only to alleviate the symptoms of OSA but also to address the underlying neuromuscular dysfunction that leads to upper airway collapse—a significant concern in sleep apnea pathology.

The Impact of Obstructive Sleep Apnea

Obstructive Sleep Apnea is a widespread condition, affecting an estimated 80 million people in the United States alone and over a billion globally. Patients often face numerous apneic events each night, leading to perilous drops in oxygen saturation and adverse long-term health impacts like cardiovascular and neurocognitive damage if untreated. Despite its prevalence, many individuals remain undiagnosed or untreated, underscoring the necessity for innovative treatment solutions like AD109.

Vision of Apnimed

Rooted in a mission to transform sleep disorder treatment, Apnimed seeks to revolutionize patient care through the introduction of novel oral therapies. By offering less invasive and more accessible treatment options, they aspire to enhance the quality of sleep and overall health for those battling OSA. As they prepare to present at ATS 2026, Apnimed embodies a future where effective management of sleep-related disorders becomes the standard, rather than an unattainable goal.

For further insights on Apnimed’s pioneering work, you can visit their website at apnimed.com and follow them on social media.